Table 2.

Therapeutic strategies targeting tau in AD drug development

Therapeutic strategy	Drug	Mechanism	Sponsor	Study population	Admin	Phase	Results	Clinical Trial Identifier	Start date	Estimated end date
Active immunotherapy	AADvac1	Active vaccine	Axon Neuro- science SE	Mild AD	IV	II	Completed	NCT02579252	2016 Mar	2019 Jun
	ACI-35	Active vaccine	AC Immune SA, Janssen	Early AD	IV	I/II	Recruiting	NCT04445831	2019 Jul	2023 Oct
Passive immunotherapy	RG7345 (RO6926496)	Monoclonal antibody	Discontinued	Healthy	IV	I	Completed	NCT02281786	2015 Jan	2015 Oct
	BIIB076 (NI-105)	Monoclonal antibody	Biogen	Healthy and AD	IV	I	Completed	NCT03056729	2017 Feb	2020 Mar
	Semorinemab (RO7105704)	Monoclonal antibody	Genentech	Mild AD	IV	II	Completed	NCT03289143	2017 Oct	2021 Jan
			Genentech	Moderate AD	IV	II	Active, not recruiting	NCT03828747	2019 Jan	2023 Oct
	Tilavonemab (ABBV-8E12)	Monoclonal antibody	AbbVie	Early AD	IV	II	Completed	NCT02880956	2016 Oct	2021 Jul
			AbbVie	Early AD	IV	II	Active, not recruiting	NCT03712787	2019 Mar	2021 Jul
	Zagotenemab (LY3303560)	Monoclonal antibody	Eli Lilly	Early AD	IV	II	Active, not recruiting	NCT03518073	2018 Apr	2021 Oct
	Gosuranemab (BIIB092)	Monoclonal antibody	Biogen,	Mild AD	IV	II	Terminated	NCT03352557	2018 May	2021 Aug
	PNT001	Monoclonal antibody	Pinteon Therapeutics	Healthy	IV	I	Completed	NCT04096287	2019 Sept	2021 Feb
	Lu AF87908	Monoclonal antibody	H. Lundbeck	Healthy and AD	IV	I	Recruiting	NCT04149860	2019 Sept	2022 Jul
	JNJ-63733657	Monoclonal antibody	Janssen	Early AD	IV	II	Recruiting	NCT04619420	2021 Jan	2025 Mar
	E2814	Monoclonal antibody	Eisai	Mild to moderate AD	IV	I/II	Recruiting	NCT04971733	2021 Jun	2024 Apr
	Bepranemab (UCB0107)	Monoclonal antibody	Hoffmann La Roche, UCB S.A	Mild cognitive impairment or mild AD	IV	II	Recruiting	NCT04867616	2021 Jun	2025 Nov

AD, Alzheimer’s disease; Admin, Route of administration; IV, intravenous